Localization of transforming growth factor-β isotypes in lesions of the human breast

McCune, Bryan K.; Mullin, Brian R.; Flanders, Kathleen C.; Jaffurs, William J.; Mullen, Larry T.; Sporn, Michael B.

doi:10.1016/0046-8177(92)90004-m

Cited by 89 publications

(32 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anti-TGF-pl was an IgG fraction of a rabbit antibody raised against a synthetic peptide corresponding to the amino-terminal 30 amino acids of TGF-p1 and has been referred to as anti-TGF-CC in some previous publications (Ellingsworth et al, 1986;Heine et al, 1987). The anti-TGF does not cross-react with TGF-P2, but does show some cross-reactivity with TGF-P3 on western blots (Heine et al, 1987;McCune et al, 1992). The anti-fastheonatal myosin heavy chain antibody (MY 32 (Sigma)) and anti-slow myosin heavy chain antibody (NOQ7.1.1A, which is the same as NOQ7.5.4D) are monoclonal antibodies whose reactivities with rat fetal muscles and myosins have been characterised (Harris et al, 1989).…”

Section: Methodsmentioning

confidence: 99%

Localisation of transforming growth factor beta 1 in developing muscles: Implications for connective tissue and fiber type pattern formation

McLennan

1993

Developmental Dynamics

View full text Add to dashboard Cite

Skeletal muscles are highly ordered mixtures of cell types, with each muscle having its own characteristic pattern of fiber types, connective tissues, and vasculature. The precursors of the myogenic and connective elements of a muscle are initially intermixed and are proliferating and differentiating together in a manner that generates an ordered array of mature cells. The molecular basis of myogenesis is unknown, although in vitro studies have revealed numerous putative regulators. The results obtained from in vitro studies are not easily related to in vivo myogenesis because of a lack of information about the localisation of the putative regulators in developing muscles. The objective of this paper was therefore to describe the spatial and temporal distribution of transforming growth factor beta 1 (TGF-pl), a small peptide that affects cultured fibroblasts, myoblasts, and vascular endothelial cells. TGF-P1-immunoreactivity was associated with the epimysia, perimysia, and vasculature of the developing muscles. The expression of TGF-91 within developing muscles had a distinct spatial and temporal pattern that correlated with the fate of adjacent myotubes. Myotubes which formed prior to the expression of TGF-PI developed into slow fibers whereas those which formed adjacent to TGF-pl-containing connective tissue matured into fast fibers. The possibility that TGF-p1 is involved in the generation of the pattern of epi-and perimysia andlor fiber types is discussed. o 1993 Wiley-Liss, Inc.

show abstract

Section: Methodsmentioning

confidence: 99%

Localisation of transforming growth factor beta 1 in developing muscles: Implications for connective tissue and fiber type pattern formation

McLennan

1993

Developmental Dynamics

View full text Add to dashboard Cite

show abstract

“…TGF-β activity is generally inhibitory to epithelial cells in vitro and has several effects on the regulation of extracellular matrix components (Sporn et al, 1986). Moreover, the cellular response to TGF-β and the presence of several isoforms could be important factors for explaining the conflicting results regarding its activity (Mizukami et al, 1990;McCune et al, 1992;Walker et al, 1992).…”

Section: Tgf-β Expressionmentioning

confidence: 99%

Tumour necrosis factor- α and transforming growth factor- β are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization

et al. 2000

View full text Add to dashboard Cite

Recent in vivo and in vitro studies have demonstrated a wide spectrum of biologic activities of cytokines in the pathogenesis and progression of malignancy. Tumour necrosis factor alpha (TNF-α) and transforming growth factor beta (TGF-β) have emerged as two of the many host-derived mediators that seem to interfere with both antiproliferative and tumorigenic effects in malignant tumours including lung cancer. However, their association with tumour prognosis or prognostic factors has not yet been completely clarified. In this study, we assessed TNF-α and TGF-β mRNA expression by RT-PCR technique in 61 NSCLC samples, demonstrating the presence of TNF-α and TGF-β mRNA in 55.74% and 45.9% of cases, respectively. We also evaluated the expression of the two distinct transmembrane TNF receptors. TNFR-I and TNFR-II, with a PCR-positive signal in 70.49% and 65.57% of cases, respectively. In 49 of the 61 cases, we evaluated the prognostic impact of the two growth-inhibiting factors using the Kaplan–Meier analysis. In the univariate analysis patients without nodal metastatic involvement ( P = 0.02), less advanced tumour stage ( P = 0.02) or TNF-α and TGF-β positive cancers ( P = 0.01 and P = 0.03) showed a favourable prognosis in terms of overall survival. Since our previous studies demonstrated a significant association between NSCLC behaviour, neoangiogenesis and bcl -2 expression, we investigated the putative relation between TNF-α and TGF-β on the one hand, and vascular count (as a measure of tumour angiogenesis) and bcl -2 protein expression, on the other hand. Our results showed a significant direct association between TNF-α and bcl -2 ( P = 0.05) and an inverse association between TNF-α and microvessel count ( P = 0.03). Moreover, as previously demonstrated, we observed a significant inverse correlation between bcl -2 protein expression and vascular count ( P = 0.05), suggesting that the favourable effect of TNF-α on clinical outcome may be related to a bcl -2-mediated low neovascular development. © 2000 Cancer Research Campaign

show abstract

“…Preliminary results on a small series of tumours show differences in distribution for the isoforms, TGF-,1I and -P2 being predominantly, but not exclusively, associated with malignant epithelial cells, while TGF-133 is largely restricted to vasculature. It is thus interesting that immunohistochemical studies may produce varying results on location of TGF-P protein depending on the antibodies employed (McCune et al, 1992). Antibodies against precursor protein produce staining in active tumour epithelium, whereas those against secreted protein point to localisation within the stromal compartment.…”

Section: Reply To Letter From Mr Benson and Professor Baummentioning

confidence: 99%

Reply to letter from Mr Benson and Professor Baum

MacCallum¹,

Miller²

1994

Br J Cancer

View full text Add to dashboard Cite

Localization of transforming growth factor-β isotypes in lesions of the human breast

Cited by 89 publications

References 26 publications

Localisation of transforming growth factor beta 1 in developing muscles: Implications for connective tissue and fiber type pattern formation

Localisation of transforming growth factor beta 1 in developing muscles: Implications for connective tissue and fiber type pattern formation

Tumour necrosis factor- α and transforming growth factor- β are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization

Reply to letter from Mr Benson and Professor Baum

Contact Info

Product

Resources

About